作者：
Edward B,Garon [1]
;
Alexander I,Spira [2]
;
Sarah B,Goldberg [3]
;
Jamie E,Chaft [4]
;
Vassiliki,Papadimitrakopoulou [5]
;
Tina,Cascone [5]
;
Scott J,Antonia [6]
;
Julie R,Brahmer [7]
;
D Ross,Camidge [8]
;
John D,Powderly [9]
;
Antoinette J,Wozniak [10]
;
Enriqueta,Felip [11]
;
Song,Wu [12]
;
Maria L,Ascierto [12]
;
Nairouz,Elgeioushi [12]
;
Mark M,Awad [13]
作者单位：
Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California. Electronic address: egaron@mednet.ucla.edu.
[1]
Co-Director, Virginia Cancer Specialists Research Institute and NEXT Oncology, Fairfax, Virginia.
[2]
Department of Internal Medicine, Yale Cancer Center, New Haven, Connecticut.
[3]
Department of Medicine, Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York, New York.
[4]
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
[5]
H. Lee Moffitt Cancer Center, Tampa, Florida.
[6]
Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
[7]
Department of Medicine-Medical Oncology, University of Colorado Cancer Center, Denver, Colorado.
[8]
Carolina BioOncology Institute, Huntersville, North Carolina.
[9]
Department of Medicine, University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania.
[10]
Deparmtent of Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
[11]
Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland.
[12]
Dana-Farber Cancer Institute, Boston, Massachusetts.
[13]
DOI
10.1016/j.jtho.2023.04.020
PMID
37146752
发布时间
2023-07-24
换一批
换一批
